Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.91 Million SEK | 292.4% |
| 2022 | 487 Thousand SEK | 81.04% |
| 2021 | 269 Thousand SEK | 333.87% |
| 2020 | 62 Thousand SEK | -33.33% |
| 2019 | 93 Thousand SEK | -49.84% |
| 2018 | 185.42 Thousand SEK | 115.5% |
| 2017 | -1.19 Million SEK | 35.84% |
| 2016 | -1.86 Million SEK | -186443500.0% |
| 2015 | 1.00 SEK | 100.0% |
| 2014 | -376 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 118 Thousand SEK | -54.44% |
| 2024 Q1 | 259 Thousand SEK | -86.45% |
| 2023 Q2 | 2.52 Million SEK | 1400.0% |
| 2023 Q4 | 1.91 Million SEK | 1140.91% |
| 2023 FY | 1.91 Million SEK | 292.4% |
| 2023 Q1 | 168 Thousand SEK | -65.5% |
| 2023 Q3 | 154 Thousand SEK | -93.89% |
| 2022 Q2 | 835 Thousand SEK | 119.35% |
| 2022 Q3 | 425 Thousand SEK | -49.1% |
| 2022 FY | 487 Thousand SEK | 81.04% |
| 2022 Q4 | 487 Thousand SEK | 14.59% |
| 2022 Q1 | -4.31 Million SEK | -1704.09% |
| 2021 Q3 | - SEK | 100.0% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 Q2 | -3.28 Million SEK | -44144210739199900.0% |
| 2021 FY | 269 Thousand SEK | 333.87% |
| 2021 Q4 | 269 Thousand SEK | 1805228441599900.0% |
| 2020 Q4 | 62 Thousand SEK | 102.07% |
| 2020 FY | 62 Thousand SEK | -33.33% |
| 2020 Q2 | 18 Thousand SEK | -79.55% |
| 2020 Q1 | 88 Thousand SEK | -5.38% |
| 2020 Q3 | -2.99 Million SEK | -16755.56% |
| 2019 Q2 | 148 Thousand SEK | -20.0% |
| 2019 Q3 | 93 Thousand SEK | -37.16% |
| 2019 FY | 93 Thousand SEK | -49.84% |
| 2019 Q4 | 93 Thousand SEK | 0.0% |
| 2019 Q1 | 185 Thousand SEK | -0.23% |
| 2018 Q3 | 168 Thousand SEK | 121.88% |
| 2018 FY | 185.42 Thousand SEK | 115.5% |
| 2018 Q1 | -868 Thousand SEK | 0.0% |
| 2018 Q2 | -768 Thousand SEK | 11.52% |
| 2018 Q4 | 185.42 Thousand SEK | 10.37% |
| 2017 Q4 | - SEK | 100.0% |
| 2017 FY | -1.19 Million SEK | 35.84% |
| 2017 Q3 | -721 Thousand SEK | -2.71% |
| 2017 Q2 | -702 Thousand SEK | -37688338022399900.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | -1.86 Million SEK | -186443500.0% |
| 2016 Q1 | -961 Thousand SEK | -96100100.0% |
| 2016 Q2 | -957 Thousand SEK | 0.42% |
| 2016 Q4 | - SEK | 100.0% |
| 2016 Q3 | -2.04 Million SEK | -113.38% |
| 2015 FY | 1.00 SEK | 100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 1.00 SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | -376 Thousand SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| AcuCort AB | -1.09 Million SEK | 273.885% |
| AlzeCure Pharma AB (publ) | -2508.00 SEK | 76296.172% |
| BioGaia AB (publ) | 181.2 Million SEK | 98.945% |
| Enzymatica AB (publ) | 11.49 Million SEK | 83.381% |
| Enorama Pharma AB (publ) | 4.29 Million SEK | 55.475% |
| Gabather AB (publ) | -1772.00 SEK | 107944.244% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 7.11 Million SEK | 73.141% |
| Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 61.742% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 42.4 Million SEK | 95.493% |
| Probi AB (publ) | 116.7 Million SEK | 98.363% |
| Swedencare AB (publ) | 398.1 Million SEK | 99.52% |
| Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 99.951% |
| Toleranzia AB | -1.34 Million SEK | 242.612% |
| Vivesto AB | - SEK | -Infinity% |